Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen

Patent metadata

Field	Value
Publication number	US-12384847-B2
Application number	US-201916967218-A
Country	US
Kind code	B2
Filing date	Feb 8, 2019
Priority date	Feb 8, 2018
Publication date	Aug 12, 2025
Grant date	Aug 12, 2025

Abstract

Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

First claim

What is claimed is:

1. A method of enhancing tumor cell death directly or indirectly, the method comprising exposing a tumor cell and a natural killer cell to a multi-specific binding protein comprising:
(a) a first antigen-binding site that binds and activates human NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) a first antibody Fc domain of human IgG1 and a second antibody Fc domain of human IgG1that together bind CD16, wherein the first and second antibody Fc domains comprise different amino acid mutations to promote heterodimerization, and the first and second antibody Fc domains each comprise an N-terminus,
wherein the first antigen-binding site is linked to the N-terminus of the first antibody Fc domain, and the second antigen-binding site is linked to the N-terminus of the second antibody Fc domain,
wherein the tumor cell is also contacted with a second therapeutic agent comprising a checkpoint blocker that is an anti-PD-1 antibody, and
wherein the tumor cell expresses the tumor-associated antigen on its surface.

2. The method of claim 1 , wherein the anti-PD-1 antibody is nivolumab.

3. The method of claim 1 , wherein the anti-PD-1 antibody is pembrolizumab.

4. The method of claim 1 , wherein the first antigen-binding site of the multi-specific binding protein binds to NKG2D in humans and non-human primates.

5. The method of claim 1 , wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

6. The method of claim 1 , wherein the multi-specific binding protein is administered in a formulation that further comprises a pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the first antigen binding site comprises a heavy chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:57, a CDR2 amino acid sequence of SEQ ID NO:58, and a CDR3 amino acid sequence of SEQ ID NO:59; and a light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:60, a CDR2 amino acid sequence of SEQ ID NO:61, and a CDR3 amino acid sequence of SEQ ID NO:62.

8. The method of claim 7 , wherein the first antigen-binding site comprises a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:47 and a light chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:48.

9. A method of treating a solid tumor, the method comprising administering an effective amount of a multi-specific binding protein to a subject in need thereof who also receives an effective amount of a second therapeutic agent comprising a checkpoint blocker that is an anti-PD-1 antibody, wherein the multi-specific binding protein comprises:
(a) a first antigen-binding site that binds and activates human NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) a first antibody Fc domain of human IgG1 and a second antibody Fc domain of human IgG1that together bind CD16, wherein the first and second antibody Fc domains comprise different amino acid mutations to promote heterodimerization, and the first and second antibody Fc domains each comprise an N-terminus,
wherein the first antigen-binding site is linked to the N-terminus of the first antibody Fc domain, and the second antigen-binding site is linked to the N-terminus of the second antibody Fc domain, and
wherein the solid tumor expresses the tumor-associated antigen on its surface.

10. The method of claim 9 , wherein the solid tumor is selected from the group consisting of B cell lymphoma, bladder cancer, breast cancer, colorectal cancer, diffuse large B cell lymphoma, esophageal cancer, follicular lymphoma, gastric cancer, gastrointestinal cancer, gastrointestinal stromal tumors, glioblastoma, head and neck cancer, melanoma, mesothelioma, multiple myeloma, myelodysplastic syndrome, renal cell carcinoma, neuroblastoma, non-small cell lung cancer, neuroendocrine tumors, ovarian cancer, pancreatic cancer, prostate cancer, sarcomas, including Ewing's sarcoma, small cell lung cancer, T cell lymphoma, testicular cancer, thymic carcinoma, thyroid cancer, urothelial cancer, cancers infiltrated by myeloid-derived suppressor cells, cancers with extracellular matrix deposition, cancers with high levels of reactive stroma, and cancers with neoangiogenesis.

11. The method of claim 9 , wherein the anti-PD-1 antibody is nivolumab.

12. The method of claim 9 , wherein the anti-PD-1 antibody is pembrolizumab.

13. The method of claim 9 , wherein the first antigen-binding site of the multi-specific binding protein binds to NKG2D in humans and non-human primates.

14. The method of claim 9 , wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain present on the same polypeptide.

15. The method of claim 9 , wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

16. The method of claim 9 , wherein the multi-specific binding protein is administered in a formulation that further comprises a pharmaceutically acceptable carrier.

17. The method of claim 9 , wherein the first antigen binding site comprises a heavy chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:57, a CDR2 amino acid sequence of SEQ ID NO:58, and a CDR3 amino acid sequence of SEQ ID NO:59; and a light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:60, a CDR2 amino acid sequence of SEQ ID NO:61, and a CDR3 amino acid sequence of SEQ ID NO:62.

18. The method of claim 17 , wherein the first antigen-binding site comprises a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:47 and a light chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:48.

19. The method of claim 9 , wherein the first antigen binding site comprises:
(a) a heavy chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:90, a CDR2 amino acid sequence of SEQ ID NO:52, and a CDR3 amino acid sequence of SEQ ID NO:91; and a light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:54, a CDR2 amino acid sequence of SEQ ID NO:55, and a CDR3 amino acid sequence of SEQ ID NO:56;
(b) a heavy chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:94, a CDR2 amino acid sequence of SEQ ID NO:64, and a CDR3 amino acid sequence of SEQ ID NO:95; and a light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:66, a CDR2 amino acid sequence of SEQ ID NO:67, and a CDR3 amino acid sequence of SEQ ID NO:68;
(c) a heavy chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:122, a CDR2 amino acid sequence of SEQ ID NO:117, and a CDR3 amino acid sequence of SEQ ID NO:123; and a light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:119, a CDR2 amino acid sequence of SEQ ID NO:120, and a CDR3 acid sequence of SEQ ID NO:121; or
(d) a heavy chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:122, a CDR2 amino acid sequence of SEQ ID NO:117, and a CDR3 amino acid sequence of SEQ ID NO:130; and a light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO:127, a CDR2 amino acid sequence of SEQ ID NO:128, and a CDR3 amino acid sequence of SEQ ID NO:129.

20. The method of claim 19 , wherein the first antigen-binding site comprises:
(a) a heavy chain variable domain comprising an amino acid

Assignees

• Dragonfly Therapeutics Inc

Inventors

• Chang Gregory P
• Cheung Ann F
• Grinberg Asya
• Gutierrez Eva
• Haney William
• Wagtmann Nicolai
• Lunde Bradley M
• Prinz Bianka

Classifications

• A61K40/4224

  Molecules with a "CD" designation not provided for elsewhere · CPC title

• A61K40/4221

  CD20 · CPC title

• A61K40/4215

  Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 · CPC title

• A61K40/4205

  Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4 · CPC title

• A61K40/421

  Immunoglobulin superfamily · CPC title